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Abstract
Introduction: Copayments are intended to decrease third party expenditure on pharmaceuticals, particularly those
regarded as less essential. However, copayments are associated with decreased use of all medicines. Publicly insured
populations encompass some vulnerable patient groups such as older individuals and low income groups, who may be
especially susceptible to medication non-adherence when required to pay. Non-adherence has potential consequences of
increased morbidity and costs elsewhere in the system.
Objective: To quantify the risk of non-adherence to prescribed medicines in publicly insured populations exposed to
copayments.
Methods: The population of interest consisted of cohorts who received public health insurance. The intervention was the
introduction of, or an increase, in copayment. The outcome was non-adherence to medications, evaluated using objective
measures. Eight electronic databases and the grey literature were systematically searched for relevant articles, along with
hand searches of references in review articles and the included studies. Studies were quality appraised using modified EPOC
and EHPPH checklists. A random effects model was used to generate the meta-analysis in RevMan v5.1. Statistical
heterogeneity was assessed using the I2 test; p.0.1 indicated a lack of heterogeneity.
Results: Seven out of 41 studies met the inclusion criteria. Five studies contributed more than 1 result to the meta-analysis.
The meta-analysis included 199, 996 people overall; 74, 236 people in the copayment group and 125,760 people in the non-
copayment group. Average age was 71.75years. In the copayment group, (verses the non-copayment group), the odds ratio
for non-adherence was 1.11 (95% CI 1.09–1.14; P =,0.00001). An acceptable level of heterogeneity at I2 = 7%, (p = 0.37) was
observed.
Conclusion: This meta-analysis showed an 11% increased odds of non-adherence to medicines in publicly insured
populations where copayments for medicines are necessary. Policy-makers should be wary of potential negative clinical
outcomes resulting from non-adherence, and also possible knock-on economic repercussions.
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Introduction
In the last decade spending on pharmaceuticals in OECD
countries has risen by 50% [1]. This has led to increased financial
pressures in health systems and many countries have attempted to
scale back public expenditure on pharmaceuticals; the US,
Canada, Australia, Ireland and South Korea have introduced
copayment policies to offset growing drug bills [2–7]. A copayment
is a fixed fee for a prescription. In theory, copayments are intended
to reduce drug expenditure by reducing moral hazard associated
with medicines supplied at reduced or zero cost. That is,
copayments dis-incentivise the collection of medicines that patients
do not consume at home or which have no role in improving
health – thus reducing waste [8]. A further function of copayments
is to generate revenue to offset drug budget costs. The success of
copayment policies, however, depends on the ability of patients to
make rational choices about which medications they should or
should not take [9–14]. Copayments may be disadvantageous if
they cause a decrease in use of medications that are beneficial to
health.
The impact of copayment policies in different countries has
been assessed in various ways, with significant differences in
populations studied, methodologies employed and outcome
measures described.
Vulnerable populations are those who have increased sensitivity
to adverse health outcomes and typically include older people and
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those on low incomes [15]. Patient groups such as these are
commonly covered by public insurance schemes such as Medicaid
and Medicare in America, or the General Medical Services
scheme in Ireland. Therefore, publicly insured populations may
provide a proxy for identifying vulnerable populations.
Assessing the effects of copayments on adherence to prescribed
medications in specific populations may offer practical insights,
rather than studying general populations; where effect sizes may
be diluted [16]. Previous reviews have suggested that patients with
low income and chronic disease are particularly susceptible to the
unfavourable effects of copayments [17] and that older patients
reduce their use of medications in the presence of copayments
[16]. Contrary to this, another review [18] stated that poorer and
older people may be less sensitive to prescription fees than other
reviews had previously reported [16,19]. A reason for this contrast
may be differing included studies in reviews, with associated
differences in heterogeneity amongst interventions, outcomes and
study designs. A review carried out by Rice et al [20] showed that
copayments are associated with a decline in health status of older
patient groups, with two notable exceptions; those with serious
health conditions and those on lower incomes who receive a
‘‘financial cushion’’ around copayments. This evidence, though, is
limited by the methodological shortcomings of included studies,
including cross-sectional and self-reported data. Furthermore, the
outcome of interest in included studies varied and contained
patient expenditure, health outcomes and drug utilization.
‘‘Utilization’’ is an umbrella term which includes the supply,
prescription, and use of medicines in a society, with attention to
the resulting medical, social, and economic consequences [21]. A
more specific outcome than utilization is adherence, which is a
component of utilization and refers specifically to ‘‘the extent to which
patients take their medicines as prescribed’’ [22]. Reviews in the past have
focused on utilization; however, the effect of copayments on
adherence is increasingly being researched. It is generally accepted
that reduced adherence, which may occur in response to a
copayment, leads to poorer health outcomes and increased costs
for a health service through hospital admissions and hospital care
[23–29]. Furthermore, improved adherence can lead to savings in
health expenditures [30,31].
One review has focused on the effects of patient cost sharing on
adherence to medicines in a general population [32]. This review
and other similar reviews which studied utilization as the main
outcome, have quantified the effects of copayments on utilization/
adherence by estimating price elasticities of demand [16,18,33,34].
Price elasticites of demand indicate how responsive demand is to
price. Variable elasticities are noted across these reviews, ranging
from 2% to 8% in a general population. Not all reviews
categorized their findings by specific population subgroups
[32,33] and none use a homogenous outcome measure. Due to
the heterogeneity of included studies in these reviews, it may be
possible that summary elasticities do not reflect the true picture,
given that it may not have been appropriate to combine individual
study effects. Despite numerical differences in elasticities, the
direction of results is agreed upon by a Cochrane review in the
broad area of cost-sharing, which used the literature published up
until 2007. This review echoes the general findings of other
reviews; a decreased use of all medicines albeit with a greater
decrease in non-essential medicines [35]. An essential medicine is
one which is said to proffer health benefits in disease and prolong
life, while a non-essential drug is useful in alleviating symptoms
only.
Because of inconsistencies in previous reviews and the lack of a
meaningful quantitative summary effect of copayments on
adherence; this review aimed to consider and quantitatively
summarise comparative studies which used an objective measure
of adherence. Publicly insured populations typically comprise
older and low income individuals, thus the effect in this population
was sought as a proxy for identifying vulnerable populations. To
date, no review has focused on publicly insured populations. It was
hoped that objective measures of adherence, namely Proportion of
Days Covered (PDC) and the ReComp Algorithm [36–40] would
reduce the heterogeneity of evidence examined. Thus, the
question this review seeks to answer is ‘‘How do copayments
affect adherence to prescribed medications in publicly insured
populations?’’
Methods
A recent Cochrane review [35] informed the selection of search
terms for this review. However, as the Cochrane review focused on
utilisation, some modifications were made to encompass terms that
would capture studies examining adherence. Study type filters
were amended to include cohort studies (Table 1). Eight
databases were searched including; PubMed, Medline(Ovid),
Cinahl, EMBASE, EconLit, SCOPUS, Web of Knowledge and
the Cochrane Library. The grey literature was also searched
through the WHO, OECD and SIGLE. The references of eligible
published studies were hand-searched, as were the references of
previously published systematic reviews [18,32–35]. There were
no language restrictions on searches and the date range extended
from 1946 to 2012. Searches were carried out between November
2011 and December 2011. Searches were updated in September
2012. For a study to be eligible for inclusion in the review the
following criteria were required: First, the participants received
healthcare from a public insurance scheme. The comparator
group was the same population/similar population who either
didn’t pay copayments or experienced no increase in copayment.
Second, the intervention was copayment; either an increase in an
existing copayment or the introduction of a copayment. Other
types of cost-sharing, for example co-insurance, were excluded.
Third, the outcome measure was non-adherence. Four commonly
used objective measures of adherence were included in search
terms; Proportion of Days Covered (PDC), Medication Possession
Ratio (MPR), Daily Defined Dose (DDD) and the ReComp
algorithm [36,37,40]. Although the DDD is generally a measure of
utilisation, it was included in this search as a conservative
approach to capturing appropriate studies as some studies
reporting DDDs may have included indications of adherence.
Non-adherence is classified as any percentage of adherence
,80%, an arbitrary but accepted cut-off [36,41]. Next, types of
studies included were randomised controlled trials, controlled
before and after studies, interrupted time series designs, repeated
measures designs, and cohort designs. The types of studies
involved were drawn from, and built upon, the study designs
used by the Cochrane Effective Practice and Organisation of Care
(EPOC) Review group. Lastly, only adjusted estimates of
adherence were included in the meta-analysis [42].
Searches were carried out by the main reviewer (SJS). Exclusion
of titles and abstracts were confirmed with DOR and CB. Authors
of any relevant abstracts which did not have a retrievable whole
paper were contacted via email for follow up on subsequent
publishing of whole papers. Data extraction was carried by SJS
and duplicated by DOR and CB using standardised data
extraction forms. Data extracted included general demographic
information, copayment value, copayment status, outcome mea-
sure used, follow up time and adjusted odds ratios. Disagreements
were resolved by discussion and where necessary involved other
authors (CBr and HW). When required, authors were contacted
Copays and Adherence to Medicines: A Meta Analysis
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by email for data. If no response was gained, a reminder email was
sent. The study was excluded if there was no response. Controlled
before and after studies and interrupted time series designs were
assessed for quality and risk of bias using a modified version of the
EPOC Data Collection Checklist and Quality Criteria for CBA
and ITS [43]. Using this tool, studies could be rated as strong,
moderate, weak or fatally flawed. A study was rated as ‘‘weak’’ if
two or more criteria were unmet. Cohort studies were assessed for
quality and risk of bias using the Effective Public Health Practice
Project component rating scale [44]. Using this tool, studies could
be given strong, moderate or weak status. A study was rated as
‘‘weak’’ if it was given two weak ratings across the constituent
criteria. Both tools for quality included an assessment of
confounding.
RevMan version 5.1 [45] was used to carry out the meta-
analysis. The log (OR) and corresponding standard error were
inputted. The summary effect measure calculated was the odds
ratio and its corresponding 95% confidence interval. Statistical
heterogeneity was assessed using the I2 test for heterogeneity in
RevMan. A conservative value of p.0.1 indicated a lack of
heterogeneity. A random effects model was used. The outcomes of
all PDC and ReCOMP studies were combined in one meta-
analysis because they both measure the same outcome; adherence.
A sensitivity analysis was performed to ensure suitability of
combination – the combination of the two measures did not distort
the conclusion. Sensitivity analyses for publication types and
demographics (gender) were also run, no differences in conclusion
were observed (Figures S1, S2, S3, S4). The medicines that
occurred in the included studies are medicines used in chronic
disease and have been referred to as being essential [35].
Therefore, a degree of homogeneity across these medicines
permits combination in one meta-analysis.
Publication bias was assessed using visual inspection of a funnel
plot generated in RevMan. Formal tests of asymmetry were not
appropriate due to similar numbers involved in studies and the
lack of more than ten studies in the meta-analysis. The small study
effect was investigated by sensitivity analysis and fixed model
random effects model comparisons.
Results
Search results and study characteristics
From the initial searches, 6 out of 22 studies met the inclusion
criteria for meta-analysis [46–51]. An additional study [52] out of
19 studies was added from a search update in September 2012 to
give 7 included studies overall. A Prisma flowchart (Figure 1)
demonstrates how the search results were obtained and sequen-
tially ruled out from final inclusion. Table 2 gives details of the 7
studies included in the meta-analysis. All studies were carried out
in the US, despite no geographical limitations in search. Four
studies focused on Medicare insurance plans [46,47,51,52] and 3
studies analysed copayment increases in Veteran Affairs [48–50].
The average age of patients included in studies was 71.75years
(range 64.8yrs to 85+yrs). Gender was evenly distributed between
copay and non-copay groups except in Veteran studies which were
predominantly male. Five studies [46–48,51,52] examined adher-
ence using the PDC measure and 2 studies [49,50] used the
ReComp measure of adherence. Four studies were cohort designs
and 3 studies were controlled before and after studies. The meta-
analysis includes 7 studies in 16 separate patient/medication
groups, because 5 studies analysed adherence to medication
groups individually or analysed patient groups at different levels of
morbidity [46,49–52]. The value of copayments ranged from $5 to
$70. Details of excluded studies are included in Table S1.
Quality assessment
Table 3 gives the details of quality assessment of the studies.
Included studies were all of weak or weak-moderate strength.
Sources of weakness were derived from characteristics imbalances
in copayment groups and non-copayment groups, along with poor
information given on follow up/attrition.
Publication bias
Asymmetry was noted in the funnel plot. Asymmetry may be
due to a publication bias, that is, authors do not publish studies of
no effect, which results in an overestimation of the true effect.
However, asymmetry may also be caused by weak methodological
Table 1. Search terms used in searches of electronic databases.
Intervention Outcome Study Filters
Cost sharing
Deductibles and coinsurance*
Capitation fee
Fees, pharmaceutical
Fees and charges
Medication adherence
Patient compliance
Pharmaceutical preparation*
Prescription drugs
Drug costs
Drug Utilization*
Drug prescriptions
Randomized controlled trial (publication type)
Controlled clinical trial (publication type)
Intervention studies
Evaluation studies (publication type)
Comparative studies (publication type)
Retrospective cohort
Textwords
Cost shar*
Co-payment
Co-pay*
Copayment
Copay*
Co payment
Co pay*
Textwords
Medication possession ratio
Defined Daily Dose
Proportion Days Covered
ReCOMP algorithm
Textwords
Experiment*
Time series
Interrupted time series
(Pre test or pretest or (posttest or post test)
Impact
Intervention*
Effect*
Evaluat*
NOT
Letter
Comment
Editorial
These search terms or variants were used in all databases
doi:10.1371/journal.pone.0064914.t001
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practices in studies. In this meta-analysis all included studies were
of weak design. The small study effect was not present.
Non-adherence when exposed to copayment
The meta-analysis included 199, 996 people overall; 74,236
people in the copayment group and 125, 760 people in the non-
copayment group. These numbers may overestimate the true
number of individuals because the 7 included studies contributed
16 separate patient groups, and there may have been some
overlap. Figure 2 shows the results of the meta-analysis which
plots the outcome, non-adherence, as affected by the exposure,
requirement to copay for prescription drugs. The summary odds
ratio for non-adherence is 1.11 (95% CI 1.09–1.14; P =,0.00001)
in the copayment group. Results were consistent across studies; an
acceptable level of heterogeneity at I2 = 7%, (p = 0.3 ) was
observed.
Discussion
This meta-analysis has found an 11% increase in odds of non-
adherence when publicly insured patients are required to copay
for their prescription medicines. This is a pertinent result because
the question regarding adherence to medicines in a cost sharing
environment was still inconclusively quantitatively answered by
prior reviews [18,33–35].
Medication classes that appeared more than once in the meta-
analysis included those for hypertension, hyperlipidaemia and
diabetes; medicines which are regarded as being essential. This
gives this meta-analysis particular relevance; because lack of
adherence to these medicines can be important clinically and
economically.
While adherence is a surrogate outcome for clinical outcomes,
there is a body of literature which allows extrapolation of this
finding to give meaningful clinical results. People with diabetes are
traditionally poor adherers to chronic medications with reported
levels of adherence as low as 50% [53]. This occurs despite the
knowledge that tight glycaemic control results in fewer complica-
tions for patients and also has economic benefits [31,54–56].
Similarly, rates of adherence to hypertensive medicines are widely
reported to be poor; with rates of adherence at 50% 1 year after
starting treatment [57]. Well-controlled hypertension is seen at
levels of adherence at over 80% [58]. Cherry et al [59] showed
approximately a double relative risk of myocardial infarction,
stroke and angina in non-adherers verses those who have ‘‘ideal’’
adherence to anti-hypertensive medicines. Their research also
outlined the economic burden of non-adherence, costing roughly
$8,500/life year gained more than full adherence. It has been
found that non-adherence to oral hypoglycaemics, anti-hyperten-
sives and statins in more than 11,000 patients with diabetes was
significantly associated with all cause hospitalisations and all cause
mortality [60]. These results have financial implications as
described by Sokol et al, who demonstrated that adherence to
medicines used to treat diabetes and hypercholesteremia reduces
expenditure in overall health costs [27]. In hypertensive disease,
the same results have been shown by McCombs et al [61]. The
result of this meta-analysis shows copayment to be an additional
risk factor for non-adherence. Given the already low adherence
profiles to these essential drugs and the associated costly
Figure 1. A PRISMA flowchart outlining the procurement of 7 included studies.
doi:10.1371/journal.pone.0064914.g001
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repercussions, an 11% increased odds of non-adherence to these
medicines may be important clinically and economically.
The results of this meta-analysis agree with the qualitative
results of reviews that have been published in the broader area of
cost-sharing and utilisation of drugs [33–35]. Previous reviews
quantified broadly defined utilisation by calculating elasticities
[18,32,34]. Nevertheless, this is the first review to encompass a
meta-analysis and give a numerical summary measure of the odds
of non-adherence when individuals are required to copay for
medicines. In addition, this review builds upon recent related
reviews such as Eaddy et al [32] by focusing solely on publicly
insured populations.
Pharmaceutical expenditure is difficult to contain at present due
to a global aging population and the increased incidence of
morbidity that this is associated with. To compound this, the
growth of the pharmaceutical bio-technology industry and the
development of biological drugs that are increasingly prescribed
will serve to maintain, if not increase, public spending on
pharmaceuticals. It is imperative for policy makers and health
economists to devise practical and balanced cost sharing policies
that do not represent a barrier to cheap, effective medicines which
produce health gains at a large population level. Such health gains
result in large financial savings by maintaining public health and
by decreased health services utilisation [27,62]. Simultaneously
however, drug expenditure policies must account for moral hazard
and attempt to confer upon the patient the notion of cost
responsibility. Due to clinical, financial and political influences
cost-sharing policies are often difficult to formulate. This meta-
analysis will contribute to the body of evidence that should be used
as a guide in future decision making.
Limitations
Despite strict inclusion and exclusion criteria which were
developed to obtain studies that would be comparable, some
differences in research methodologies persisted. First, follow up
times in the included studies varied widely, ranging from 3 months
to 2 years. Secondly, this type of research is vulnerable to
confounding and not all studies controlled for the same
confounders. For example 2 studies attempted to control for an
introduced fee for physician care [49,50], whereas another paper
experiences the same physician fee, but does not control for this
confounder [48]. Thirdly, the included studies were of weak to
moderate quality. Given the non-experimental nature of this
research this is a problem that is difficult to avoid. Regardless, the
quality of included studies should be borne in mind when
interpreting the summary effect measure. There are methodolog-
ical strengths in the included studies such as propensity score
matching that attenuate the biased nature of some observational
research designs. However propensity score matching can leave
residual confounding between groups and cannot account for
unknown or immeasurable confounding as a randomised con-
trolled trial only can.
It may be worth noting that qualitative analysis of interrupted
time series studies [5] may provide an interesting insight into
patient behaviours over a period of time. Analysis of such results
would show how adherence fluctuates in the months preceding the
policy change, for example, adherence to b-blockers introduced
after a myocardial infarction can fall rapidly even before a copay
policy change [5]. However, a meta-analysis of such data would be
impractical, thus the method employed in the meta-analysis
presented here is a pragmatic way of analysing the key research
question.
Next, the studies included in this review were concerned with
drugs that act primarily in cardiovascular disease and diabetes.
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Therefore the results of the meta-analysis may not be extrapolated
to other disease groups such as cancer or pain. However, given
that cardiovascular disease, ischaemic heart disease and diabetes
are included in the top ten causes of death in high income
countries [63] these results still have high relevancy and a wide
generalisabilty. Despite this, external validity may suffer as some
studies excluded the poorest members of society due to different
coverage status for these people [46,47]. Furthermore, the studies
included in this review focus on elderly populations. Therefore, the
results may not be applicable to younger vulnerable populations.
However, given that elderly populations are the biggest users of
pharmaceuticals [64,65], this review still gives pertinent informa-
tion. Further analysis in younger, low income populations should
be undertaken to fill in the information gaps.
There may have been a degree of publication bias present.
Efforts were made to overcome this problem in the development of
the search strategy which encompassed 8 electronic databases, the
grey literature and hand-searching. The potential presence of
publication bias should be kept in mind when interpreting the
summary effect of this meta-analysis.
Lastly, this meta-analysis was explicit in the intervention
analysed i.e., an introduced or increased copayment. Results from
this analysis may not be extendable to other cost-sharing policies
such as co-insurance, because the effects of different cost-sharing
policies are not necessarily always comparable [4]. However, there
is no reason why these results cannot be extrapolated in a
directional manner for other policies.
Conclusions
This meta-analysis showed an 11% increased odds of non-
adherence to medicines in publicly insured populations involved in
a system where copayments for medicines are required. Reduc-
tions in adherence to medications, especially essential medicines,
can be detrimental to health status and causes increases in
expenditure via hospital admissions. Hence, the results of this
meta-analysis should be taken into account at a policy and health
systems level to aid in striking a balance between the financial
benefits and financial repercussions of cost-sharing policies.
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